Hematopoiesis in the Mouse Model
Hematopoietic stem cells arise in the embryo from an hemangioblast present in yolk sac and aorta-gonadmesonephros. They then migrate into fetal liver and spleen, entering bone marrow in the late embryonic period [1] . Numbers of HSC increase in bone marrow and spleen in the neonatal period and are then maintained in those organs for life [2, 3] . HSC migration into bone marrow at birth then determines bone as the dominant site for hematopoiesis in adults. HSC have also been identified in extramedullary sites in the steady state and small numbers also mobilize through blood and lymph into sites like liver, spleen, brain, lung and intestine [4, 5] . Infection, inflammation, or drug treatment can lead to expansion in the number of hematopoietic stem/progenitor cells (HSPC) circulating in blood and entering tissues like spleen and liver [6, 7] . Despite the small numbers of HSPC present in extramedullary tissues in the steady state, this fact should not discount their importance or potential contribution to the development of the immune system and immune responsiveness. Findings from this lab indicate that spleen in the steady state contains HSC [2] and that these undergo myelopoiesis within spleen giving rise to a novel type of dendritic-like antigen presenting cell [8] .
The Hematopoietic Stem Cell
Bone marrow is a very rich source of HSC and for decades bone marrow transplants have provided HSC for regeneration of the hematopoietic system in humans. HSC have distinguishing properties of self-renewal, asymmetric cell division, and ability to clonally regenerate all hematopoietic cell types. Methodology for sorting HSC from bone marrow using specific antibodies and flow cytometry [9] has become a standard technique in many labs. HSC are heterogeneous, comprising cells with both long-term and short-term reconstitution capacity [10, 11] . Long-term reconstituting HSC are commonly isolated from murine bone marrow as lineage (Lin) − Sca-1 + c-kit + Flt3 − cells [11] and can be further purified as the CD150 + CD48
− subset of Lin − Sca1 + ckit + bone marrow [12, 13] . Epigenetic imprinting of HSC also contributes to differences in hematopoietic potential [14] . Given the level of heterogeneity amongst HSC, it is important to consider them in relation to their tissue niche 2 Stem Cells International of origin, their distinct hematopoietic potential, and to use this knowledge to inform HSC transplantation in the clinic. Most studies have concentrated on the more prevalent HSC in bone marrow with less attention given to HSC in extramedullary sites like spleen. While HSC from tissue sites like bone marrow, cord blood and spleen can reconstitute all cell lineages, there has been no comprehensive study of their relative capacity to produce a range of hematopoietic cell subsets. The hematopoietic support capacity of different tissue niches is also a factor not yet investigated in terms of hematopoietic output. Recent evidence that spleen supports the development of distinct dendritic-like antigen presenting cells suggests that spleen may contribute in a distinct, tissuespecific manner to hematopoiesis.
The Spleen in Hematopoiesis
HSC represent a rare subset in adult mouse spleen. They are however readily detectable by their long-term reconstitution ability upon adoptive transfer into irradiated host mice [2, 3] (Figure 1 ). The weaker contribution of splenic HSC compared with bone-marrow-derived HSC to hematopoiesis in the normal animal has been reported [15] . It has long been assumed that spleen fills the role of an emergency or backup site for cell development at times of stress or disease. Indeed, the importance of bone marrow over spleen in hematopoiesis is evident since neonatally splenectomised mice can maintain normal bone marrow hematopoiesis [16] . However, a distinct role for spleen in hematopoiesis has not yet been fully investigated in terms of development of individual cell subsets. During embryogenesis, spleen harbours myeloid cells seeding from fetal liver and does not appear to become colonized with HSC until around the time of birth [3] . Evidence that splenectomy in newborn mice results in a dramatic increase in colony forming cells in liver suggests that HSC entering spleen at this time may seed directly into spleen from fetal liver rather than from bone marrow [3] . Spleen could therefore become colonized by HSC during development resulting in an endogenous HSC population. Such a model would not however preclude later or additional entry of bone-marrow-derived HSC at times of stress or inflammation, or following stem cell transplantation.
Spleen is also a central organ for development of dendritic cells (DC) that initiate immune responses by taking up and presenting antigen to lymphocytes. Murine spleen contains multiple subsets of DC including the CD8α − and CD8α + conventional(c)DC, plasmacytoid(p)DC [17] , and regulatory DC which are not well characterised [18] . Monocyte-derived DC are also found in spleen but only under conditions of inflammation [19] . Very few markers distinguish these subsets and they are best distinguished by their distinct function in immunity. Both cDC subsets are powerful T-cell activators, although the CD8α − cDC are located in the marginal zone of spleen where antigen enters from blood, while the CD8α + cDC are located in the Tcell areas where they are poised for T-cell stimulation. The CD8α
− cDC preferentially activate a T-helper(h)2 response with T-cell production of interleukin(IL)-4 and IL-10, while CD8α + cDC preferentially induce a Th1 response marked by interferon (IFN)-γ production [20, 21] . While both subsets of cDC can activate CD4 + and CD8 + T cells, the CD8α + cDC subset has been shown to be superior at antigen crosspresentation [22] . Plasmacytoid DC are distinct in that they reside mainly in blood in a precursor form, often referred to as p-preDC. They are distinct by their capacity to produce high levels of IFN-α in response to viruses [23] . Regulatory DCs represent a poorly defined class of DCs which are inhibitory rather than stimulatory for T cells, producing factors like IL-10 and nitric oxide [18, 24] . In contrast to cDC and pDC, mo-DCs are not detectable in spleen in the resting state. They develop from blood monocytes in response to inflammatory factors. Tumour necrosis factor α/inducible nitric oxide synthase producing (Tip) DC derive from monocytes and enter tissues where they function as strong T-cell activators [25] .
An essential element of DC biology is the definition of progenitors and precursors since this underpins the formation of lineages of cells with distinct function. Initially cDC and pDC progenitors were defined as a Flt3 + subset amongst common myeloid and lymphoid progenitors (CMP/CLP) in bone marrow [26] . Recent evidence now points to a monocyte/dendritic progenitor (MDP) in bone marrow which gives rise to all monocyte/macrophage and dendritic type cells [27, 28] , as well as a more committed common dendritic progenitor (CDP) for cDC and pDC in bone marrow [29, 30] . While CDP and MDP are not present in spleen or blood [31] , spleen does harbour more differentiated cDC precursors which have a high turnover and are replaced by blood-borne precursors migrating from bone marrow [32] . Studies with parabiotic mice that share a circulatory system, suggest that some splenic DC might arise from endogenous progenitors [33] , although others have questioned that result [34] . The presence of an endogenous hematopoietic progenitor in spleen that differentiates to give a novel and distinct dendritic-like cell is now indicated by the findings described below.
A Novel Antigen Presenting Cell Subset in Spleen
Distinct myeloid dendritic-like cells have been discovered as a subset in murine spleen [35] on the basis of similarity with dendritic-like cells identified previously which develop in splenic longterm cultures (LTC) [36] [37] [38] . LTC-derived DC and the in vivo subset of "L-DC", have a characteristic immature phenotype as CD11c lo CD11b hi MHC-II − CD8α − cells, distinguishing them from cDC, pDC, and monocytes [35] ( Figure 2 ). They are large, endocytic cells specialized in crosspresentation of antigen to CD8 + T cells, a function usually attributed to CD8α + cDC [39] . LTC-DC are also distinct by their very weak ability to activate CD4 + T cells and their MHC-II − phenotype, properties which distinguish them from all of the common subsets of CD8α + cDC, CD8α
− cDC, and pDC [35, 37, 40] . Since LTC-DC can be derived from GM-CSF −/− mice [41] , they do not resemble monocytederived DC that develop in response to inflammatory factors like GM-CSF and TNF-α [19] . An isolation procedure was optimised to reveal the in vivo equivalent cell type to LTC-DC [35] . This procedure distinguished CD8α + cDC, CD8α
− cDC, pDC and monocytes on the basis of CD11b, CD11c, MHC-II and CD8α expression, from a population of cells of large size (FSC hi ) resembling LTC-DC by their CD11c lo CD11b hi MHC-II − CD8α − phenotype and their high endocytic capacity for soluble antigen (Figure 3 ). These cells have been tentatively named "L-DC," since they resemble a DC more than a myeloid cell. L-DC are phenotypically and functionally distinct from monocytes/macrophages, cDC and pDC. They are distinct as CD11c + cells that are highly cross-presenting, a property which distinguishes them from common subsets of macrophages and monocytes [40] . Recent evidence for uniform expression of F4/80 and CD11c, but not Ly6G, also distinguishes L-DC from neutrophils [42] . The immune potential of this in vivo subset is under continued investigation in terms of both T-cell and B-cell immunity. Already we know that L-DC share similar antigen cross-presenting function for CD8 + T-cell activation with LTC-DC [35] . Like LTC-DC, they are also unable to activate CD4 + T cells, consistent with the absence of MHC-II expression [37, 40] . Despite their distinct functional potential, the lineage origin of L-DC relative to other known splenic myeloid and DC subsets, is still unknown.
The distinctiveness of L-DC from monocytes, cDC subsets and granulocytes has been confirmed by transcriptome analysis of subsets sorted as shown in Figure 3 . Principal Components Analysis of the data indicated a broad separation of overall gene expression between L-DC and other subsets, with CD8α + and CD8α − cDC the most closely related subsets (Figure 4 ). L-DC specifically express high levels of Treml4, a gene recently identified as expressed by CD8α + but not CD8α − cDC and by splenic red pulp and metallophilic macrophages [43] . This gene encodes a receptor that binds late apoptotic and necrotic cells, consistent with cross-presenting capacity related to the uptake of dead and dying cells from blood. The relationship between L-DC and other DC and macrophage cell types is currently under investigation. 
Hematopoiesis Leading to L-DC Production In Vitro
Coculture assays are now used instead of LTC to produce L-DC in vitro. These involve overlay of Lin − BM or T/Bcell-depleted spleen cell suspensions over competent splenic stroma [40] . The splenic stromal line STX3 and its 5G3 clone originated from a long-term splenic culture that had lost hematopoietic progenitors over time and passage [40] . The 5G3 clone of STX3 has been characterized as an immature endothelial-like cell [44, 45] , unique in its phenotype and function as a supporter of in vitro hematopoiesis of L-DC. There also appears to be no equivalent stromal cell line reported in the literature. Cells produced in cocultures over 35 days both phenotypically and functionally resemble LTC-DC as well as the in vivo L-DC subset [8, 40] . Cocultures can therefore be used to identify L-DC progenitors amongst sorted cell subsets by their capacity to seed stroma for continued L-DC production in vitro. Indeed, the continuous nature of LTC which produce dendritic-like cells over several years [36] , as well as the ability of STX3 or 5G3 stroma to support in vitro hematopoiesis of L-DC for up to a year [46] , suggests that the L-DC progenitor may represent a selfrenewing HSPC.
The development of L-DC in LTC depends on the maintenance of a population of small progenitors [38, 47] . In fact, the requirement for differentiation of progenitors was demonstrated by sorting the small progenitor population in LTC and showing that these cells produced L-DC upon transfer to stromal cocultures [38] . L-DC were however shown to undergo several rounds of proliferation in bromodeoxyuridine labeling experiments [47] . The production of dendritic-like cells by differentiation from HSPC maintained within LTC as opposed to proliferation of L-DC was also confirmed by gene profiling of subtracted libraries prepared between the purified small and large cells maintained in LTC [48] . These studies showed that small cells resemble HSPC, while large cells reflect myeloid dendritic cells. More recent studies have involved phenotypic characterization of progenitors. Over many experiments, progenitor activity was found to be enriched within the subset of Lin − ckit + CD34
−/+
"small" cells in LTC, a phenotype reflective of described subsets of HSC differing in terms of long-term or shortterm reconstituting capacity [11] . Highly purified, sorted HSC from bone marrow have now been shown to seed STX3 cocultures to produce L-DC, but only when contact is maintained with stroma [46] . Cells produced were found to phenotypically resemble L-DC. Overall, these results align the L-DC progenitor with the HSC subset in bone marrow. This finding is particularly important in terms of the relationship between the L-DC progenitor and the progenitors of cDC and pDC which have been identified as MDP, CDP and myeloid progenitors (MP), which are present in bone marrow but not spleen [31] . One hypothesis is that splenic niches are distinct from bone marrow niches and can support the direct differentiation of HSC to give L-DC in the apparent absence of committed myeloid or dendritic progenitors like the MDP, CDP and MP. The relationship between these progenitors and a putative L-DC progenitor in spleen is not known and warrants further investigation.
Identification of L-DC Progenitors in Spleen
To delineate the L-DC progenitor in mouse spleen, Lin − splenocytes were assessed for expression of ckit and other markers of early hematopoietic progenitors followed by sorting of subsets of interest. Sorted subsets were each assessed for their hematopoietic potential in cocultures of competent stroma. They were also tested in vivo for capacity to reconstitute lethally irradiated CD45-allotype distinct host mice also given syngeneic bone marrow to aid recovery [8] ( Figure 1 ). The Lin − ckit lo spleen subset produced exclusively L-DC in cocultures, and the Lin − ckit hi subset produced predominantly L-DC with a few cDC-like cells that were not maintained over time. However, only Lin − ckit hi splenocytes, and not the Lin − ckit lo or Lin − ckit − subsets, showed multilineage reconstitution in vivo consistent with the presence of HSC [8] . The Lin − ckit hi population of spleen therefore contains long-term reconstituting HSC as well as L-DC progenitors, while the Lin − ckit lo fraction contains only L-DC progenitors. One explanation is that there is a common progenitor within each of these two populations. Another is that there are distinct progenitors within the two subsets and that the stroma supports differentiation of ckit hi progenitors to give ckit lo progenitors. The relationship between the L-DC progenitor and the HSC subset in spleen is unclear at present. These findings are also consistent with evidence that bone-marrow-derived HSC can seed stroma for L-DC production and that the L-DC progenitor maintained in LTC is represented by a Lin − ckit + CD34 +/− subset. Splenic stroma therefore appears to impose specific differentiative capacity on HSC, irrespective of their origin from spleen or bone marrow. In terms of the characterization of L-DC progenitors endogenous to spleen, a first goal will be to fractionate subsets of splenic Lin − ckit + cells further and to identify the minimum subset that produces L-DC in cocultures.
Does Hematopoiesis in Spleen Involve an Endogenous Progenitor?
Many studies now indicate a specific role for splenic niches in the development of the novel antigen presenting cell subset, namely L-DC. While the in vitro evidence is direct and compelling, it is a harder task to delineate L-DC production in vivo as dependent on hematopoiesis occurring in spleen and arising from an HSPC endogenous to spleen. In experiments involving adoptive transfer of stem cells into irradiated mice (Figure 1 ), the issue of where in the animal hematopoiesis occurs is not clear. Transferred stem cells can migrate to and localize in multiple niches in spleen and bone marrow. In these sites, they can undergo hematopoiesis and then migrate into other lymphoid areas. Another more direct method to delineate hematopoiesis specific to splenic HSC involves ectopic grafting of allotype-distinct spleen or spleen fragments under the kidney capsule of splenectomized mice and monitoring the output of donor graft-derived mature cells on the basis of allotype markers. We recently published successful engraftment of neonatal spleen fragments under the kidney capsule of splenectomized mice [49] . Most grafts retained donor-type HSC and showed development of some donor-type myeloid cells at 2 weeks. However, recruitment of host HSC, lymphocytes and myeloid cells into grafts was also evident [49] . The spleen microenvironment therefore appears to support myelopoiesis and possibly L-DC development. The development of individual subsets of myeloid cells is yet to be analysed more completely using this model. Indirect evidence that spleen supports hematopoiesis and the specific differentiation of L-DC also comes from chimera studies. These studies compared the relative ability of splenic versus bone marrow HSC to generate the different myeloid and DC subsets including L-DC [2] . In several studies, analysis of the relative numbers of donor : host progeny cells representing each of the common DC and myeloid subsets produced in chimeras identified a distinct developmental bias towards donor L-DC over other myeloid and DC subsets [2] . The only explanation for this finding is that splenic niches preferentially support the development of L-DC from HSC. Another consideration is whether the microenvironment in which HSC develop conditions their hematopoietic capacity. In terms of stem cell transplantation, it will be important to determine whether HSC arising in BM, spleen, or fetal liver can adopt distinct differentiative capacity after residence in splenic niches.
Conclusion
A history of published work now supports the hypothesis that the splenic L-DC subset described here represents a functionally distinct tissue-specific antigen presenting cell type that develops within spleen from endogenous HSPC. Its development is entirely dependent on endothelial niches within spleen although bone-marrow-derived HSC can also differentiate within this niche to produce L-DC. The hypothesis that spleen contains an endogenous HSC laid down during embryogenesis would be consistent with evidence for tissue-specific hematopoiesis of L-DC.
The identification of a novel antigen presenting cell subset with unique immune function is of significant immunological interest. It is therefore important to define the hematopoietic pathways in spleen that lead to development of these dendritic-like cells, especially since these cells do not appear to have a lineage origin in common with other described cDC and myeloid subsets. Indeed, there are now a number of examples in the literature of tissuespecific antigen presenting cells developing from endogenous progenitors maintained in distinct tissue sites. For example, Langerhans cells in skin arise from epidermal progenitors that colonize embryonic skin [50] , and microglia represent antigen presenting cells in brain which develop from selfrenewing progenitors induced to proliferate after inflammation [51] . These examples support a model for compartmentalization of the immune response by the production of tissue-specific antigen presenting cells, and specialization of immunity in tissues colonized by particular pathogens. A full understanding of hematopoiesis occurring in extramedullary sites will be essential knowledge for therapeutic practice in immunotherapy and indeed in HSC transplantation.
